Treatment Options for Chronic Parvovirus Viremia in Pediatric Heart Transplant Patients in a Tertiary Care Center
Poster May 09, 2018
Rachel Cruz, Carla Duff, Diane Krasnopero, Sonya Joychan, David Lindsay, Daime Nieves, Maryssa Ellison, Zsofia Long, Panida Sriaroon, Alfred Asante-Korang, Jolan E. Walter
OBJECTIVE: Parvovirus viremia may occur in pediatric heart transplant patients with secondary T cell lymphopenia and history of thymectomy. While the treatment option for these patients is high dose intravenous immunoglobulin (HDIvIg), it may not be well tolerated in all patients. We present treatment outcomes in three cardiac transplant patients with parvovirus viremia.
RESULTS: Of the three patients, two responded well to treatment; however, one patient’s viral load remained at over one million copies and developed severe side effects of aseptic meningitis with HDIvIg. Compared to the other two cases, this patient had severe reduction of T cell count that likely contributed to the persistence of high viral load. In order to improve this patient’s quality of life as well as reduce the healthcare costs, a new treatment option was explored. Facilitated subcutaneous immunoglobulin treatment was initiated and resulted in a dramatic decrease in parvovirus viral loads with no adverse effects.
CONCLUSION: Pediatric cardiac transplant patients with severely reduced T cell counts may be at risk of developing chronic parvovirus viremia with high viral load. Although most patients respond well to HDIvIg, subcutaneous route may serve as an alternative to treatment refractory cases.
Primary Human Hepatocyte (PHH) culture provides the closest in vitro model to human liver that can produce a metabolic profile of a given drug very similar to that found in vivo. Recently we have developed an easy-to-assemble user-friendly in vitro Primary Human Hepatocyte (PHH) 3D-spheroid modelREAD MORE